Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory High Quality
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili weCrizotinib (CAS: 877399-52-5) kunye nomgangatho ophezulu.I-Ruifu Chemical inokubonelela ngenkonzo yehlabathi jikelele, ixabiso elikhuphisanayo, inkonzo egqwesileyo, encinci kunye nezixa ezininzi ezikhoyo.Thenga iCrizotinib,Please contact: alvin@ruifuchem.com
| Igama leMchiza | Crizotinib |
| Izithethantonye | Xalkori;PF-02341066;iCrozotinib;Crizotinib Xalkori;3- [1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5-(1-Piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;(R) -3-[1-(2,6-Dichloro-3-Fluorophenyl) ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Inombolo yeCAS | 877399-52-5 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C21H22Cl2FN5O |
| Ubunzima beMolekyuli | 450.34 |
| Indawo yokunyibilika | 192℃ |
| Ukuxinana | 1.47±0.10 g/cm3 |
| Ubushushu boGcino | Ubushushu beGumbi |
| Imvelaphi | Shanghai, China |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder |
| Ukuchongwa | Ngo-IR, HPLC |
| Ukucaca kwesisombululo | Ukuhambelana noMgangatho |
| Ilahleko ekomisweni | ≤1.00% |
| Intsalela kwi-Ignition | ≤0.50% |
| Ukungcola Okunxulumeneyo | (nge-HPLC) |
| Ukungacoceki Okukodwa | ≤0.50% |
| Ukungcola ngokupheleleyo | ≤1.00% |
| Iintsimbi ezinzima | ≤20ppm |
| Isivavanyi | ≥99.0% |
| Izinyibilikisi ezishiyekileyo | Hlangana neNkcazo |
| Beka ubomi kwishelufa | Iinyanga ezingama-24 |
| Umgangatho woVavanyo | Umgangatho woShishino |
Umqulu:Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina isikhongozeli sivalwe ngokuqinileyo kwaye usigcine kwindawo epholileyo, eyomileyo (2~8℃) kunye nendawo yokugcina impahla engena moya ikude kwizinto ezingahambelaniyo.Khusela ukukhanya kunye nokufuma.
Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.
Inkcazo yoKhuseleko 24/25 -Kuphephe ukudibana nolusu kunye namehlo.
Ii-ID ze-UN UN 3077 9 / PGIII
WGK eJamani 3
Ikhowudi yeHS 2933990099
I-Hazard Class IRRITANT
I-Crizotinib (i-CAS 877399-52-5), (i-Crizotinib, i-Xalkori R), i-ATP enamandla kunye ne-ATP ekhuphisanayo encinci ye-molecule inhibitor ye-ALK kunye ne-c-Met.Ngo-Agasti 2011, i-United States FDA yavuma i-Crizotinib yonyango lwe-anaplastic lymphoma kinase (ALK) iphinde yahlengahlengisa umhlaza wemiphunga ongeyena omncinci omncinci (NSCLC).I-Crizotinib yi-inhibitor ekhuphisanayo ye-ATP ye-tyrosine kinases c-MET (i-Mesenchymal-Epithelial Transition Factor) kinase (i-cellular IC50 = 8 nM) kunye ne-ALK (i-cellular IC50 = 20 nM), zombini ezo zinjongo ezibalulekileyo zekhemotherapy yomhlaza.Xa i-crizotinib ivavanya i-selectivity ngokuchasene nezinye i-kinases yafunyanwa ukuba ine-enzyme ye-IC50 ngaphakathi kwe-100-fold multiples ye-c-MET ye-13 ye-120 kinases evavanyiwe.Kwiimvavanyo zeselula, i-crizotinib yafunyanwa inhibitha i-RON (i-recepteur d'origine nantais) kinase enefestile ye-10-fold selectivity over c-MET.
I-Crizotinib (PF-02341066) I-Crizotinib yi-c-Met enamandla kunye ne-ALK inhibitor, amaxabiso e-IC50 kwi-cell assay yayiyi-11 nM kunye ne-24 nM, ngokulandelanayo.Kwakhona i-inhibitor enamandla ye-ROS1 enexabiso le-Ki elingaphantsi kwe-0.025 nM.I-Crizotinib inokwenza i-autophagy kwiindidi ezahlukeneyo zomhlaza wemiphunga ngokuthintela indlela ye-STAT3.
I-Crizotinib yi-inhibitor enamandla kwaye ekhethiweyo ye-mesenchymal-epithelial transition factor (c-MET) kinase kunye ne-anaplastic lymphoma kinase (ALK).I-Crizotinib yinto enokuthi ibe yi-antitumor agent.Ngo-Agasti 2011, i-United States FDA yavuma i-crizotinib yonyango lwe-anaplastic lymphoma kinase (ALK) iphinde yahlengahlengisa umhlaza wemiphunga ongewona omncinci (NSCLC).
I-Crizotinib (Xalkori (R), i-Pfizer), evunyiweyo kwi-2011, yayiyi-inhibitor yokuqala evunyiweyo ejolise kwi-anaplastic lymphoma kinase (ALK).I-ROS protooncogene i-1-encoded kinase (ROS1) yeklasi ye-tyrosine kinase ye-insulin receptor kunye ne-MET proto-oncogene-encoded kinase ye-hepatocyte growth factor receptor (HGFR) iklasi enye i-kinases ejoliswe yi-crizotinib.Xa ivunyiwe kwi-2011, i-crizotinib yayingowokuqala iyeza elijolise ngokukodwa kwizigulane ze-NSCLC.Nangona kunjalo, ukuchasana ne-crizotinib ngokuqhelekileyo kwabonwa malunga neenyanga ze-8 emva kwesicelo sokuqala kwaye ngaphezu kwesiqingatha sezigulane eziphathwe nge-crizotinib zifumana iziphumo zecala lesisu.Kwi-2016, i-crizotinib iye yavunywa i-ROS1-positive NSCLC yi-FDA.
I-Crizotinib (i-Xalkori) yi-receptor yomlomo ye-tyrosine kinase inhibitor eboniswe kunyango lwezigulane ezinomdlavuza we-cell lung oluphambili okanye lwe-metastatic olungeyona encinci (NSCLC).Imiphumo eqhelekileyo yokusetyenziswa kwe-Xalkori ibandakanya usulelo oluphezulu lokuphefumla, isicaphucaphu, ukuhlanza, intlungu yesisu, ukuncipha kokutya, ukuphuthelwa, isiyezi, ukudinwa, urhudo, ukuqunjelwa, irhashalala okanye ukurhawuzelelwa, iimpawu ezibandayo (impumlo edibeneyo, ukuthimla, umqala obuhlungu), ukuphazamiseka okanye ukubetha, okanye ukudumba ezandleni okanye ezinyaweni zakho.
